Twist Bioscience Corporation Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Twist Bioscience Corporation (TWST) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $26.36 per share for the 9-month period ending 2022-06-30, per its 10-Q filed 2022-08-08.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2022-08-08
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-12-31 was $83.07, a 31.27% increase year-over-year.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $30.33.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-12-31 was $63.28.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $42.80, a 106.17% increase from fiscal 2020.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $20.76, a 37.85% increase from fiscal 2019.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $15.06, a 112.71% increase from fiscal 2018.
- Twist Bioscience Corporation share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $7.08, a 6.79% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2022-06-30 | $26.36 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $73.39 10-Q · filed 2022-05-06 | |||
| 2021-12-31 | $83.07 10-Q · filed 2022-02-09 | |||
| 2021-09-30 | $42.80 10-K · filed 2021-11-23 | |||
| 2021-06-30 | $38.74 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $30.33 10-Q · filed 2021-05-07 | |||
| 2020-12-31 | $63.28 10-Q · filed 2021-02-09 | |||
| 2020-09-30 | $20.76 10-K · filed 2021-11-23 | |||
| 2019-09-30 | $15.06 10-K · filed 2021-11-23 | |||
| 2018-09-30 | $7.08 10-K · filed 2020-11-27 | |||
| 2017-09-30 | $6.63 10-K · filed 2019-12-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |